University of California, San Francisco
Noriyuki Kasahara is Principal Investigator at the Brain Tumor Center at University of California, San Francisco (UCSF). Previously he was a Professor of Cell Biology & Pathology at the University of Miami and served as Co-Leader of the Viral Oncology Program at the Sylvester Comprehensive Cancer Center. Past positions also include Professor of Medicine & Molecular Pharmacology at the University of California, Los Angeles (UCLA), where he was Director of the UCLA Vector Core & Shared Resource facility at the Jonsson Comprehensive Cancer Center for over a decade. Prior to this, he also established and directed Vector Core facilities as faculty at the University of Southern California (USC). Dr. Kasahara has more than 30 years of experience and has authored more than 140 peer-reviewed articles in the fields of gene therapy and genetic engineering. He pioneered the development of tumor-selective retroviral replicating vectors (RRV) for gene therapy of cancer, now in first-in-human multi-center clinical trials sponsored by Tocagen Inc.
Dr. Kasahara serves as a member of the Scientific Committee on Cancer Gene & Cell Therapy for the American Society of Gene & Cell Therapy. He is also on the Board of Directors of the Japan Society of Gene & Cell Therapy, and is a Past President of the International Society for Cell & Gene Therapy of Cancer. He is a member of the Scientific Advisory Boards of Tocagen Inc., POC Medical Systems Inc., the Mendez National Institute of Transplantation Foundation, and is on the Board of Advisors for OneLegacy. He is also a Board-certified clinical pathologist specializing in transplant immunogenetics, and serves as Associate Medical Director of the HLA clinical laboratory for VRL Eurofins’ Los Angeles Operations. Dr. Kasahara trained with Professor Y. W. Kan at UCSF, a pioneer in the field of genetic diagnostics and recipient of the Lasker Award.Return to Leadership